DB18130InvestigationalGene Therapies
DYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). It is being investigated for the treatment of Duchenne... It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.
- Code names
- DYNE-251
Resolves to
Compound
What you can answer from here — as of June 04, 2026
Which companies are running trials of DYNE-251, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account